Nova Eye Medical (ASX:EYE) Shares Gain: Why Is the Stock Rising?

Sonal Goyal

13 November 2026 01:19 PM AEDT

Nova Eye Medical (ASX:EYE) Shares Gain: Why Is the Stock Rising?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Nova Eye Medical shares were trading at $0.165 during the 13 November 2026 session, up 6.45%.
Quarterly sales reached US$6.3 million, up 30% on the prior corresponding period, with trailing annual Revenue of US$25.1 million.
The company reported positive EBITDA for the quarter and Liquidity of A$4.1 million at 30 September 2026.

During the Trading session on 13 November 2026, Nova Eye Medical Ltd (ASX:EYE) shares were trading at $0.165, up 6.45%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Nova Eye Medical is a medical technology company developing ophthalmic treatment technologies and devices for the global interventional glaucoma market. Its latest update was its Quarterly Report and Appendix 4C for the three months ended 30 September 2026, released on 27 October 2026.

Sales growth and trailing revenue

Sales in the quarter were US$6.3 million, and the company said sales growth has accelerated since 30 June 2026. Trailing annual revenue is now US$25.1 million. Sales and EBITDA guidance for FY27 has been confirmed.

Cash flow and profitability

The company generated A$0.5 million of operating cash inflow in the quarter, compared with an outflow of A$0.8 million in the prior corresponding period. It recorded positive EBITDA for the quarter. Liquidity at 30 September was A$4.1 million, made up of A$2.1 million of cash and A$2.0 million of unused Debt facility.

Reporting change

Nova Eye Medical said financial reporting in US dollars will begin in the first half of FY27.

Sector context

Glaucoma treatment is a large and ageing patient market, and new interventional devices must gain clinical acceptance and hospital reimbursement before wide adoption. Medical device companies in this area often manage a balance between growth Investment and the timing of cash generation.

Risks investors are watching

Quarterly results can be influenced by the timing of orders and shipments, and a single quarter of positive EBITDA does not confirm a sustained trend. Liquidity of A$4.1 million includes a debt Facility that will need to be managed. Competition, regulatory approvals and currency movements, given the shift to US dollar reporting, are also relevant.

What to watch ahead

Investors will look for the December quarter sales figures, whether positive EBITDA continues, and progress against FY27 guidance. The first US dollar reporting period in the first half of FY27 will also be followed.

Final Word

Nova Eye Medical's latest quarterly report shows growing sales, positive EBITDA and confirmed FY27 guidance. Its coming quarters will show whether the improvement is sustained.

FAQs

Q: What were Nova Eye Medical's sales in the September 2026 quarter?

A: Sales were US$6.3 million, up 30% on the prior corresponding period.

Q: How much liquidity did the company have at 30 September 2026?

A: Liquidity was A$4.1 million, comprising A$2.1 million of cash and A$2.0 million of unused debt facility.

Q: When will the company begin reporting in US dollars?

A: Financial reporting in US dollars will commence in the first half of FY27.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.